Date & Time
April 6, 12:00 PM ET / 9:00 AM PT
Webinar Details provided upon RSVP Approval
About the Event
Bilayer Therapeutics is developing a new platform technology that could soon join GLP-1 drugs like Wegovy and Ozempic in the obesity revolution.
Bilayer’s technology is based on the targeted and localized use of the natural regulators of the colon’s hormonal function to treat a wide range of gastrointestinal and metabolic diseases, including diabetes and obesity.
Join our webinar with Bilayer President & CEO, Thomas Collet, to hear details about this platform technology with a market potential in excess of $100 billion.